Patents by Inventor Lawrence F. Colwell, Jr.

Lawrence F. Colwell, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • C-21 hydroxylated FK-506 antagonist
    Patent number: 5225403
    Abstract: Described is a process for producing a new FK-506 antagonist agent, a C-21 hydroxylated analog of FR-900520 under novel fermentation conditions utilizing the novel microorganism, Streptomyces hygroscopicus (Merck Culture Collection MA 6832) ATCC No. 55166. The macrolide antagonist is useful in preventing and/or counteracting accidental or inadvertent FK-506 overdosage in an FK-506 therapeutic program designed to prevent autoimmune diseases or human host rejection of foreign organ transplants, e.g. bone marrow, liver, lung, kidney and heart transplants.
    Type: Grant
    Filed: June 25, 1991
    Date of Patent: July 6, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Laszlo R. Treiber, Georgette Dezeny, Lawrence F. Colwell, Jr., Byron H. Arison, Francis Dumont
  • Synthesis of protease inhibitor
    Patent number: 5192668
    Abstract: A dipeptide isostere is the biotransformed product after incubation with a culture of Streptomyces. It inhibits HIV protease, and is useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as a compound, pharmaceutically acceptable salt, pharmaceutical composition ingredient, whether or not as a prodrug or as a combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: February 27, 1992
    Date of Patent: March 9, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Laszlo R. Treiber, Lawrence F. Colwell, Jr., Byron H. Arison, Georgette Dezeny, Russell B. Lingham, Wayne J. Thompson, Suresh K. Balani
  • Method of hydroxylation with ATCC 55086
    Patent number: 5187074
    Abstract: A novel dipeptide isostere is the biotransformed product after incubation with a culture of Streptomyces. It inhibits HIV protease, and is useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as a compound, pharmaceutically acceptable salt, pharmaceutical composition ingredient, whether or not as a prodrug or as a combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: February 20, 1992
    Date of Patent: February 16, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Laszlo R. Treiber, Russell B. Lingham, Byron H. Arison, Lawrence F. Colwell, Jr., Georgette Dezeny, Nancy E. Kohl
  • C-31 methylated FR-900520 cyclic hemiketal immunosuppressant agents
    Patent number: 5149701
    Abstract: Described is a process for producing a new immunosuppressant, a C-31 desmethyl, C-19/C-22 cyclic hemiketal biotransformation analog (Compound I) of FR-900520, under novel fermentation conditions utilizing the novel microorganism, Streptomyces, lavendulae ATCC No. 55209. Also disclosed is the C-31 methylated devivative (Compound II) of Compound I produced by enzymatic methylation using 31-O-desmethylimmunomycin O-methyl transferase, (DIMT), a methyl transferase enzyme. The macrolide immunosuppressants are useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow, liver, lung, kidney and heart transplants.
    Type: Grant
    Filed: August 1, 1991
    Date of Patent: September 22, 1992
    Assignee: Merck & Co., Inc.
    Inventors: Ali Shafiee, Louis Kaplan, Shieh-Shung T. Chen, Byron H. Arison, Lawrence F. Colwell, Jr., Francis Dumont